Genomic Tests
Comprehensive Genomic Profiling using Next-Generation Sequencing with Machine/deep Learning
Solid Tumors
Liquid Trace™:
Solid Tumor Profile- TAT
5-7 Days - Indications
All solid tumors Chromosomal abnormalities, gene amplifications, HRR
Fusions: ALK, ROS1, RET,
NTRK1/2/3, and more.
BRAF, CIC, EWSR1, PD-L1,
MET exon 14 skipping
and various alternative splicing,
MET, HER2, PIK3CA, PTEN, EBV, HPV, Gene amplifications, AKT1,
RAS, HER2, MYC, EGFR, TTV, HTLV-1 status, T- & B-cell clonality analysis
Monitor therapeutic response
- Sample Type
Peripheral blood, Plasma, CSF - Sample Requirements
Peripheral blood: 8-10 ml.
EDTA tube preferred
CSF: 7-10 mL. Clear tubes - Results Reported
DNA+RNA - Monitoring
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor
Profile Plus™- TAT
7-10 Days - Indications
All solid tumors
Fusions: ALK, ROS1, RET,
NTRK1/2/3, and more.
BRAF, CIC, EWSR1, PD-L1,
MET exon 14 skipping
and various alternative splicing, MET, HER2, EGFR,
Gene amplifications, PIK3CA, PTEN, TTV,
AKT1, RAS, TMB, MSI, EBV, HPV, HTLV-1 status, and HRD Cancer of unknown primary (CUP)
T- & B-cell clonality analysis
- Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor
Profile™ 434
DNA Genes
DNA Genes
- TAT
5-7 Days - Indications
All solid tumors:
Mutations in 434 genes, copy number
variation and chromosomal structural
abnormalities, TMB, MSI, HRD
- Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor Fusion / Expression Profile
>1600
RNA Genes
RNA Genes
- TAT
7-10 Days - Indications
All Solid tumors:
Fusion: ALK, ROS1, RET, BRAF,
NTRK1/2/3, FGFR1/2/3/4, CIC,
EWSR1 & other sarcoma genes
Expression: PD-L1, MYC, CCND1,
MET, FGFR1/2/3/4, Ki67, ERBB2, MDM2, EBV, HPV, HTLV-1 status Alternative splicing: MET exon 14
skipping, EGFRvIII, NTRK,
Mutations in more than 1600 genes, TTV,
T- & B-cell clonality analysis
- Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Liquid Trace™:
Hematology Profile- TAT
5-7 Days - Indications
All hematologic neoplasms
including lymphoma
multiple myeloma, acute lymphoblastic leukemia,
acute myeloid leukemia,
MDS, TTV, CMML, MPN,
VEXAS syndrome, EBV, and HRV, HTLV1 status and quantification
Chromosomal abnormalities, and gene amplifications,
T- & B-cell clonality analysis
Monitor therapeutic response
- Sample Type
Peripheral blood, Plasma, CSF
- Sample Requirements
Peripheral blood: 8-10 ml.
EDTA tube preferred
CSF: 7-10 mL. Clear tubes - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Profile Plus™- TAT
7-10 Days - Indications
All hematologic neoplasms including lymphoma
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia
Includes IgHv
Chromosomal abnormalities, EBV, HRV, HTLV-1 status, and gene amplifications, TTV,
T- & B-cell clonality analysis
- Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Profile™ 302
DNA Genes
DNA Genes
- TAT
5-7 Days - Indications
All hematologic neoplasms
including lymphoma
MDS, CMML, AML, MPN (JAK2, CALR, MPL),
MRD, multiple myeloma, and other
hematologic diseases
- Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test